|10th September 2020||Heek G Jan Van||7,000||Open or private purchase||$2.97||$20,790.00|
|31st July 2020||William F Doyle||896||Open or private sale||$76.39||$68,443.65|
|16th June 2020||Jeryl L Hilleman||8,797||Grant/award etc.||$0.00|
|10th June 2020||Jeryl L Hilleman||2,541||Grant/award etc.||$0.00|
|26th May 2020||Frederick W Ahlholm||8,339||Open or private sale||$15.00||$125,085.00|
|11th May 2020||William F Doyle||31,332||Open or private sale||$63.73||$1,996,725.70|
|8th May 2020||William F Doyle||58,767||Exercise of derivative||$63.84||$3,751,685.28|
|8th May 2020||William F Doyle||31,903||Open or private sale||$63.50||$2,025,872.40|
|7th May 2020||William F Doyle||58,768||Exercise of derivative||$64.77||$3,806,403.36|
|7th May 2020||William F Doyle||30,993||Open or private sale||$64.74||$2,006,517.81|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 6/10.
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. Its product pipeline includes Roluperidone, Seltorexant, MIN-117, and MIN-301. The company was founded by Rogerio Vivaldi Coelho in 2007.